Chemical formula: C₂₁H₃₀O₂ Molecular mass: 314.469 g/mol PubChem compound: 644019
Cannabidiol is indicated for the treatment of seizures associated with Lennox‑Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N03AX24 | N Nervous system → N03 Antiepileptics → N03A Antiepileptics → N03AX Other antiepileptics | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| EPIDIOLEX Oral solution | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| EPIDYOLEX Oral solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Cannabidiol is an active ingredient of these brands:
United States (US)Australia (AU)Austria (AT)Brazil (BR)
Croatia (HR)Ecuador (EC)France (FR)Italy (IT)Lithuania (LT)New Zealand (NZ)
Romania (RO)Spain (ES)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
